ASX Runners of the Week: Zelira, Linq, Dalaroo and Osteopore
Zelira Therapeutics secured a $33 million investment aimed at accelerating the development and regulatory review of its autism treatment, highlighting...
Read Full Article →Create a free account to set price alerts and get notified when rates hit your targets.
Sign In with GoogleIt's free and takes seconds
Zelira Therapeutics secured a $33 million investment aimed at accelerating the development and regulatory review of its autism treatment, highlighting...
Read Full Article →The FDA's approval of Wegovy underscores critical challenges and opportunities Novo Nordisk must navigate in the U.S. market, impacting its financial...
Read Full Article →The agreement enables Zydus Lifesciences to exclusively market a newly authorized multiple sclerosis medication in the U.S., potentially enhancing rev...
Read Full Article →The recent court decision enables Avadel Pharmaceuticals to continue advancing clinical studies and potentially secure regulatory clearance for its tr...
Read Full Article →Manage your PRO subscription and extension settings.
By signing in, you agree to our Terms and Privacy Policy
Free accounts can set 3 custom rates per week. Upgrade to Pro for unlimited custom rates.
Web Pro includes
Free accounts have 5 lifetime exports. Upgrade to Pro for unlimited exports.
Web Pro includes
Free accounts can lookup 5 historical dates. Upgrade to Pro for unlimited historical rates.
Web Pro includes
Historical charts beyond 1 year are available with Web Pro subscription.
Web Pro includes
Export directly to your cloud storage with Web Pro subscription.
Web Pro includes
Choose Card Theme
=